Advanced

Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

Bendtzen, Klaus; Geborek, Pierre LU ; Svenson, Morten; Larsson, Lotta; Kapetanovic, Meliha C and Saxne, Tore LU (2007) In Ugeskrift for Laeger 169(5). p.420-423
Abstract (Swedish)
Abstract in Danish

Infliximab er effektiv ved reumatoid artritis (RA), men behandlingssvigt er hyppige. Sera fra 106 RA-patienter monitoreredes med en radioimmunoassay (RIA) for funktionel infliximab og en RIA for anti-infliximab-antistof. S-infliximab varierede betydeligt, f.eks. 0-22 μg/ml forud for tredje infusion, og efter seks måneder var 44% antistofpositive. Lav S-infliximab var forbundet med antistofudvikling og senere terapisvigt, og høje antistofniveauer kunne relateres til dosisøgning, bivirkninger og terapiophør. Farmakologisk monitorering kan formentlig optimere behandlinger med anti-tumornekrose-antistof.
Abstract
Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.
Please use this url to cite or link to this publication:
author
organization
alternative title
Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication
publishing date
type
Contribution to journal
publication status
published
subject
in
Ugeskrift for Laeger
volume
169
issue
5
pages
420 - 423
publisher
Den Almindelige Danske Lægeforening
external identifiers
  • pmid:17280636
ISSN
0041-5782
language
Danish
LU publication?
yes
id
dbd70585-c136-47c1-b75a-184b69ddf7dd (old id 1138514)
alternative location
http://www.ugeskriftet.dk/LF/UFL/2007/5/pdf/VP51189.pdf
date added to LUP
2008-08-19 11:28:52
date last changed
2016-11-15 13:09:50
@article{dbd70585-c136-47c1-b75a-184b69ddf7dd,
  abstract     = {Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.},
  author       = {Bendtzen, Klaus and Geborek, Pierre and Svenson, Morten and Larsson, Lotta and Kapetanovic, Meliha C and Saxne, Tore},
  issn         = {0041-5782},
  language     = {dan},
  number       = {5},
  pages        = {420--423},
  publisher    = {Den Almindelige Danske Lægeforening},
  series       = {Ugeskrift for Laeger},
  title        = {Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation},
  volume       = {169},
  year         = {2007},
}